

To: (10)(2e) [(10)(2e)]@rivm.nl
From: (10)(2e) @radboudumc.nl
Sent: Mon 9/14/2020 9:13:08 AM
Subject: FW: European COVID-19 vaccine trial network
Received: Mon 9/14/2020 9:13:15 AM

Denk dat dit meer bij jullie hoort.

Van: (10)(2e) (10)(2e) @CTUC.de>
Verzonden: maandag 14 september 2020 0:33
Aan: (10)(2e) <(10)(2e)@radboudumc.nl>
Onderwerp: European COVID-19 vaccine trial network

Dear colleague,

The EU is seeking to establish a pan-European site network for upcoming COVID-19 vaccine trials of all phases, including postmarketing. National network building efforts are already under way in several member states, notably (10)(2a) and (10)(2a) (10)(2a) commissioned the German Center for Infection Research (DZIF) to pool these efforts and perform capacity mapping of EU clinical trial sites for COVID-19 vaccine studies. This will be approached in close collaboration with national network coordinators.

As a first step, we are compiling a list of interested clinical trial sites and affiliated networks, followed by developing a site capability questionnaire and a linked database.

If you are interested in joining this trans-national vaccine platform, please let us know until **Wednesday, 16th September 2020**.

We would also appreciate your suggestions for further potential sites and/or points of contact for vaccine networks in your country.

With best regards,

(10)(2e)

(10)(2e) MD, FACP, FIDSA, FAAM, FECMM

Chair | Translational Research | [CECAD](#) Cluster of Excellence | University of Cologne

Scientific Director | [Center for Clinical Trials](#) | University Hospital

National Hub [DZIF-CTU](#) and [IMI-COMBACTE](#)

Consultant | Infectious Diseases | [Dep. I for Internal Medicine](#) | University Hospital

ECMM Diamond Excellence Center | [www.ecmm.info](#)

Kerpener Str. 62 | 50937 Cologne | Germany

Tel. +49 : (10)(2e) | Fax +49 : (10)(2e) | Mobile +49 : (10)(2e) | skype : (10)(2e) | (10)(2e)



De informatie in dit bericht is uitsluitend bestemd voor de geadresseerde. Aan dit bericht en de bijlagen kunnen geen rechten worden ontleend. Heeft u deze e-mail onbedoeld ontvangen? Dan verzoeken wij u het te vernietigen en de afzender te informeren. Openbaar maken, kopiëren en verspreiden van deze e-mail of informatie uit deze e-mail is alleen toegestaan met voorafgaande schriftelijke toestemming van de afzender. Het Radboudumc staat geregistreerd bij de Kamer van Koophandel in het handelsregister onder nummer 41055629.

The content of this message is intended solely for the addressee. No rights can be derived from this message or its attachments. If you are not the intended recipient, we kindly request you to delete the message and inform the sender. It is strictly prohibited to disclose, copy or distribute this email or the information inside it, without a written consent from the sender. Radboud university medical center is registered with the Dutch Chamber of Commerce trade register with number 41055629.